Daxor Corporation (DXR), Thursday announced the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA).
The company says that its new Daxor BVA device represents a significant leap forward in diagnostic technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume.
"This submission represents a long-anticipated milestone in our commitment to patients and healthcare providers," said Michael Feldschuh, Daxor's CEO and President. "Developed under a U.S. Department of Defense contract, our next-generation analyzer promises to deliver unprecedented speed, accessibility, and accuracy in blood volume management, with the potential to meaningfully improve medical care and patient outcomes."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.